Ivy Foundation Funds New Brain Cancer Research Consortium
$3M Stage I Project Aims to Improve Personalized Medicine for Patients
PALO ALTO, Calif. (Business Wire EON/PRWEB ) July 8, 2008 --
Today, the Ben and Catherine Ivy
Foundation (Ivy Foundation), a newly formed family foundation
dedicated to improving survival and quality of life for patients with
brain tumors, announced funding for the Ivy Genomics-Based Medicine
Project.
The Ivy Genomics-Based Medicine Project (Ivy G.B.M. Project) is a
collaboration among nine U.S. institutions working together to try to
better understand how the genetic differences in individual brain tumors
can potentially inform the prediction of what will be the most effective
treatment option for each patient. This project will categorize tumors
by molecular profiling and, for the first time in brain cancer research,
test each tumor against a wide spectrum of treatments to match
differences in response with the profiles.
“Currently, all patients get basically the
same treatment without taking into account the genetic profile of their
tumor,” said Catherine Ivy, Founder of the Ivy
Foundation. “The end goal of this research
initiative is to identify how tumors with different genetic features
respond to a set of treatment regimens and ultimately, it is hoped,
provide physicians with the tools they need to offer brain tumor
patients the most effective treatment options based on the specific
genetic profile of their tumor.”
The $3,000,000 Ivy G.B.M Project grant was awarded to the Translational
Genomics Research Institute (TGen). Under the leadership of Michael
Berens, Ph.D., TGen will coordinate and manage the two-stage project
spanning four to five years as well as provide their expertise in
genomics based research.
Stage I of The Ivy G.B.M Project will start immediately and researchers
will be working on an aggressive 18-month timeline with clear milestones
and deliverables. Stage I creates a new consortium of nine academic
laboratories utilizing models for predicting treatment response based on
the genetic profile of a patient’s tumor.
Real-time collaborative linkage and project-specific communication are
provided through the support of 5AM Solutions of Reston, Virginia. The
successful completion of Stage I will form the basis for funding Stage
II, a clinical trial for patients with recurrent GBM.
“The Ivy Foundation’s
fast and flexible approach to brain cancer research combined with the
unique gathering of exceptional researchers from leading medical
institutions across the United States is already generating several ‘firsts’
in brain cancer research,” said Dr. Berens. “The
Ivy G.B.M. Project was initiated at unprecedented speed; institutional
agreements were signed in a remarkable four months and, because of the
collaborative nature of the project, researchers will now be able to
compare results across institutions on a diverse set of tumors and
treatment regimen response patterns. The size, scope and potential
impact this project will have for patients with brain cancer is simply
huge.”
Ivy G.B.M. Project Phase One project leaders and institutions include:
|
--
|
|
Michael E. Berens, Ph.D.
|
|
|
|
Translational Genomics Research Institute
|
|
|
|
--
|
|
Antonio Chiocca, M.D., Ph.D. and Sean Lawler, Ph.D.
|
|
|
|
Ohio State University
|
|
|
|
--
|
|
Howard Colman, M.D., Ph.D.
|
|
|
|
The University of Texas M. D. Anderson Cancer Center
|
|
|
|
--
|
|
G. Yancey Gillespie, Ph.D.
|
|
|
|
University of Alabama at Birmingham
|
|
|
|
--
|
|
C. David James, Ph.D.
|
|
|
|
University of California, San Francisco
|
|
|
|
--
|
|
Tom Mikkelsen, M.D.
|
|
|
|
Henry Ford Hospital
|
|
|
|
--
|
|
Jann Sarkaria, M.D.
|
|
|
|
Mayo Clinic, Rochester, Minnesota
|
|
|
|
--
|
|
Andrew Sloan, M.D.
|
|
|
|
Case Western Reserve University School of Medicine
|
|
|
|
--
|
|
Craig Webb, Ph.D.
|
|
|
|
Van Andel Research Institute
|
“We are proud to partner with TGen and these
fine institutions on a project that exemplifies what The Ivy Foundation
is all about – we see data sharing among
researchers and medical institutions as a necessary component to moving
the field of brain cancer research forward and instrumental in getting
results quickly to the patients who need them,”
said Catherine Ivy.
About The Ben and Catherine Ivy Foundation
The Ivy Foundation is the nation’s largest
privately funded foundation dedicated to improving survival and quality
of life for people diagnosed with a brain tumor. Our approach is to fund
research in gliomas for improved diagnostics and treatments for
patients. In its inception year, 2008, The Ivy Foundation will grant
$12,000,000 to patient-focused research.
The Ivy Foundation is committed to funding research projects which
embody the concept of Patient-Focused Research. Patient-Focused Research
(PFR) keeps the patient and relevant clinical issues at the center of
every research project and encompasses three main components:
-
Exchange – Fosters collaboration between
institutions and disciplines and creates an on-going, back and forth
dialogue between the lab and the clinic.
-
Urgency – Each Ivy Foundation project
expedites processes to get results focused on improving the lives of
patients.
-
Personalization – PFR also addresses the
genetic differences among tumors with the aim of improving diagnostics
and treatments for each patient diagnosed with a brain tumor.
About TGen
The Translational Genomics Research Institute (TGen) is a non-profit
organization dedicated to conducting groundbreaking research with life
changing results. Research at TGen is focused on helping patients with
diseases such as cancer, neurological disorders and diabetes. TGen is on
the cutting edge of translational research where investigators are able
to unravel the genetic components of common and complex diseases.
Working with collaborators in the scientific and medical communities,
TGen believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process.
See the original story at: http://eon.businesswire.com/releases/project/research/prweb1083944.htm
Post Comment: Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1Db3VwLVpldGEtVGhpci1FbXB0LVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|